Indivior Pharmaceuticals, Inc. (DELISTED) (INDV:DL)
36.28
+0.91
(+2.57%)
USD |
NASDAQ |
Nov 02, 16:00
Indivior Pharmaceuticals Enterprise Value : 4.477B for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 4.477B |
| October 30, 2026 | 4.370B |
| October 29, 2026 | 4.356B |
| October 28, 2026 | 4.299B |
| October 27, 2026 | 4.293B |
| October 26, 2026 | 4.274B |
| October 23, 2026 | 4.263B |
| October 22, 2026 | 4.365B |
| October 21, 2026 | 4.301B |
| October 20, 2026 | 4.299B |
| October 19, 2026 | 4.193B |
| October 16, 2026 | 4.025B |
| October 15, 2026 | 4.163B |
| October 14, 2026 | 4.227B |
| October 13, 2026 | 4.376B |
| October 12, 2026 | 4.451B |
| October 09, 2026 | 4.424B |
| October 08, 2026 | 4.379B |
| October 07, 2026 | 4.459B |
| October 06, 2026 | 4.432B |
| October 05, 2026 | 4.443B |
| October 02, 2026 | 4.410B |
| October 01, 2026 | 4.371B |
| September 30, 2026 | 4.426B |
| September 29, 2026 | 4.605B |
| Date | Value |
|---|---|
| September 28, 2026 | 4.639B |
| September 25, 2026 | 4.514B |
| September 24, 2026 | 4.535B |
| September 23, 2026 | 4.524B |
| September 22, 2026 | 4.557B |
| September 21, 2026 | 4.480B |
| September 18, 2026 | 4.403B |
| September 17, 2026 | 4.498B |
| September 16, 2026 | 4.340B |
| September 15, 2026 | 4.325B |
| September 14, 2026 | 4.354B |
| September 11, 2026 | 4.357B |
| September 10, 2026 | 4.359B |
| September 09, 2026 | 4.390B |
| September 08, 2026 | 4.337B |
| September 04, 2026 | 4.410B |
| September 03, 2026 | 4.397B |
| September 02, 2026 | 4.423B |
| September 01, 2026 | 4.365B |
| August 31, 2026 | 4.409B |
| August 28, 2026 | 4.402B |
| August 27, 2026 | 4.452B |
| August 26, 2026 | 4.514B |
| August 25, 2026 | 4.531B |
| August 24, 2026 | 4.556B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Supernus Pharmaceuticals, Inc. | 1.317B |
| Bristol Myers Squibb Co. | 158.36B |
| Eli Lilly & Co. | 1.371T |
| Ligand Pharmaceuticals, Inc. | 6.973B |
| Amneal Pharmaceuticals, Inc. | 9.674B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 137.00M |
| Revenue (Quarterly) | 356.00M |
| Total Expenses (Quarterly) | 219.00M |
| EPS Diluted (Quarterly) | 1.123 |
| Gross Profit Margin (Quarterly) | 85.67% |
| Profit Margin (Quarterly) | 38.48% |
| Earnings Yield | 9.96% |
| Operating Earnings Yield | 13.65% |
| Normalized Earnings Yield | 11.29 |